MedTrace Logo

Proxalutamide Treatment for Hospitalized COVID-19 Patients

NCT04728802 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 645

Last updated 2021-06-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for hospitalized COVID-19 male and female patients.

Conditions

  • Covid19
  • SARS (Severe Acute Respiratory Syndrome)

Interventions

DRUG

Proxalutamide

Proxalutamide 300mg q.d

DRUG

Placebo

Placebo pill

Sponsors & Collaborators

  • Applied Biology, Inc.

    lead INDUSTRY

Principal Investigators

  • Flavio Cadegiani, MD · Applied Biology, Inc.

  • Andy Goren, MD · Applied Biology, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-04-15
Completion
2021-04-15

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04728802 on ClinicalTrials.gov